| 000 | 01419 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250511222236.0 | ||
| 264 | 0 | _c19910520 | |
| 008 | 199105s 0 0 eng d | ||
| 022 | _a0066-4804 | ||
| 024 | 7 |
_a10.1128/AAC.34.12.2442 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYajko, D M | |
| 245 | 0 | 0 |
_aIn vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cDec 1990 |
||
| 300 |
_a2442-4 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xcomplications |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xpharmacology |
| 650 | 0 | 4 |
_aCiprofloxacin _xpharmacology |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEthambutol _xpharmacology |
| 650 | 0 | 4 | _aFluoroquinolones |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aMycobacterium avium Complex _xdrug effects |
| 650 | 0 | 4 |
_aMycobacterium avium-intracellulare Infection _xetiology |
| 650 | 0 | 4 |
_aRifampin _xpharmacology |
| 700 | 1 | _aSanders, C A | |
| 700 | 1 | _aNassos, P S | |
| 700 | 1 | _aHadley, W K | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 34 _gno. 12 _gp. 2442-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.34.12.2442 _zAvailable from publisher's website |
| 999 |
_c2094368 _d2094368 |
||